Long-acting injectable antipsychotic using MedinCell’s technology receives FDA IND clearance to initiate clinical activities

A second long-acting injectable antipsychotic using MedinCell’s technology has received FDA IND* clearance to initiate clinical activities. A first-in-human study is expected to start in the second half of 2019.

“We have achieved our goal of having at least one clinical trial authorization per year”, stated Christophe Douat, CEO of MedinCell. “This third product reaching clinical stage confirms the high versatility of our BEPO® technology and the strong know-how of our team in successfully customizing the technology for different compounds.”

mdc-TJK is one of three antipsychotic products in development based on MedinCell’s technology. The others include a research product in clinical Phase 3 studies and another in preclinical stage.